ovarian Brenner tumor
diseaseOn this page
Also known as benign ovarian Brenner tumorbenign ovarian Brenner tumourBrenner neoplasm of ovaryBrenner neoplasm of the ovaryBrenner tumorBrenner tumor of ovaryBrenner tumor of the ovaryBrenner tumourBrenner tumour of ovaryBrenner tumour of the ovaryovarian Brenner neoplasmovary Brenner tumorovary Brenner tumour
Summary
ovarian Brenner tumor (MONDO:0002370) is a cancer and 23 clinical trials. Top therapeutic interventions include paclitaxel, belinostat, and bevacizumab. A subtype of ovarian epithelial tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 23
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ovarian Brenner tumor |
| Mondo ID | MONDO:0002370 |
| DOID | DOID:2636 |
| NCIT | C3872 |
| SNOMED CT | 254859006 |
| UMLS | C5234884 |
| MedGen | 1716777 |
| GARD | 0009397 |
| Anatomy (UBERON) | UBERON:0000992 |
| Is cancer (heuristic) | yes |
Also known as: benign ovarian Brenner tumor · benign ovarian Brenner tumour · Brenner neoplasm of ovary · Brenner neoplasm of the ovary · Brenner tumor · Brenner tumor of ovary · Brenner tumor of the ovary · Brenner tumour · Brenner tumour of ovary · Brenner tumour of the ovary · ovarian Brenner neoplasm · ovarian Brenner tumor · ovary Brenner tumor · ovary Brenner tumour
Disease family
This is a subtype of ovarian epithelial tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › ovarian Brenner tumor
Related subtypes (10): ovarian squamous cell neoplasm, ovarian mucinous neoplasm, ovarian seromucinous tumor, ovarian papillary tumor, ovarian mucinous adenofibroma, ovarian adenoma benign, borderline epithelial tumor of ovary, malignant epithelial tumor of ovary, ovarian clear cell tumor, ovarian serous tumor
Subtypes (1): malignant ovarian Brenner tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 23.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 8 |
| PHASE2 | 7 |
| PHASE3 | 5 |
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00565851 | PHASE3 | ACTIVE_NOT_RECRUITING | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT01167712 | PHASE3 | ACTIVE_NOT_RECRUITING | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00108745 | PHASE3 | UNKNOWN | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00262847 | PHASE3 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT01492920 | PHASE3 | WITHDRAWN | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy |
| NCT02101775 | PHASE2 | ACTIVE_NOT_RECRUITING | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00059787 | PHASE2 | COMPLETED | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma |
| NCT00466960 | PHASE2 | COMPLETED | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy |
| NCT00888615 | PHASE2 | COMPLETED | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT00939809 | PHASE2 | COMPLETED | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT00993616 | PHASE2 | COMPLETED | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin |
| NCT02122185 | PHASE2 | COMPLETED | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00002913 | PHASE1 | COMPLETED | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer |
| NCT00060359 | PHASE1 | COMPLETED | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
| NCT00079430 | PHASE1 | COMPLETED | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00085358 | PHASE1 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) |
| NCT00814086 | PHASE1 | COMPLETED | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
| NCT00989651 | PHASE1 | COMPLETED | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT01074411 | PHASE1 | COMPLETED | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT01294293 | PHASE1 | COMPLETED | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
| NCT00897442 | Not specified | COMPLETED | Collecting Tumor Samples From Patients With Gynecological Tumors |
| NCT01080521 | Not specified | COMPLETED | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy |
| NCT01275664 | Not specified | TERMINATED | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PACLITAXEL | 4 | 12 |
| BELINOSTAT | 4 | 1 |
| BEVACIZUMAB | 4 | 1 |
| ERLOTINIB | 4 | 1 |
| GEMCITABINE HYDROCHLORIDE | 4 | 1 |
| GRANISETRON | 4 | 1 |
| METFORMIN | 4 | 1 |
| PACLITAXEL POLIGLUMEX | 3 | 2 |
| VELIPARIB | 3 | 2 |
| ACETYLCARNITINE | 3 | 1 |
| ELESCLOMOL | 3 | 1 |
| ADAVOSERTIB | 2 | 1 |
| CHEMBL399538 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |